The global demand for Dacryocystitis Treatment Market is presumed to reach the valuation of nearly USD XX MN by 2026 from USD XX MN in 2019 with a CAGR of XX% under the study period of 2020 - 2026.
Dacryocystitis is an infection occurs secondarily to obstruction within the nasolacrimal duct the resultant backup and stagnation of tears within the lacrimal sac. It causes pain, swelling, and redness over the inner aspect of the lower eyelid and epiphora. The aetiology of dacryocystitis can be categorised into chronic, acute, acquired and congenital causes. The treatment varies with aetiology, the treatment includes conservative treatment such as warm compresses, Crigler massages, antibiotic treatment, lacrimal probing, however most patients eventually require surgical treatment. Surgical practices include balloon dacryoplasty, nasolacrimal stenting, and nasolacrimal intubation.
Growing prevalence of dacryocystitis is driving the market growth. There are distinct patterns of prevalence as per geographical variation in terms of aetiology according to the local climate in infective keratitis, females are afflicted more commonly by dacryocystitis with 70-83% of cases. It is more common in Whites than in Negros and more common in India as being a tropical country. Ciprofloxacin and vancomycin are the most effective antibiotics against dacryocystitis in both acute and chronic type. Topical antibiotics have low therapeutic value due to the lack of access to the lacrimal system secondary to blockage in the tear drainage and also insufficient penetration into the local soft tissue. However, most of the people consider watering from eyes as minor discomfort and avoid themselves from presenting to the physician as they are unaware of the deleterious complication.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of dacryocystitis treatment.
The entire dacryocystitis treatment market has been sub-categorized into product and end use. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
By End Use
- Institutional Sales
- Retail Sales
This section covers regional segmentation which accentuates on current and future demand for dacryocystitis treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Europe Dacryocystitis Treatment Market By Revenue (USD MN)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the dacryocystitis treatment market include Pfizer Inc., Abbott Laboratories, Glaxosmithkline Plc, Mylan Inc., Cipla Limited. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.